Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04943575 · ClinicalTrials.gov registry record · NA

Study to Evaluate the Efficacy of EZC Pak in Adults With Upper Respiratory Infection (URI)

A NA study of Common Cold, sponsored by PPC Pharmaceuticals.

Completed
Registry status
NA
Development phase
360
Enrollment target
1
Study location

NCT04943575 is a NA study of Common Cold that has completed, run by PPC Pharmaceuticals. The registered enrollment target is 360 participants, roughly in line with the 362-participant average among 5 other Common Cold trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04943575, a NA study of Common Cold, has completed, sponsored by PPC Pharmaceuticals.

COMPLETED
Registry status
NA
Development phase
360 participants
Enrollment target
1
Study location

Study Summary

A randomized-controlled interventional clinical trial to evaluate the effectiveness of EZC Pak \& EZC Pak+D for the treatment of the common cold and/or a URI.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT EZC Pak
  • DIETARY_SUPPLEMENT EZC Pak +D

Study Locations (1)

California

  • Citruslabs - Santa Monica

Trial Details

FieldValue
Enrollment Target 360 participants
Start Date 2021-06-01
Est. Completion 2022-01-30
Phase NA

Sponsor

PPC Pharmaceuticals

1 total trials

What the Registry Record Tells You About NCT04943575

The ClinicalTrials.gov registry entry for NCT04943575 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 362-participant average among 5 other Common Cold trials with a reported enrollment target. The listed sponsor is PPC Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Common Cold appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT04943575 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04943575 about?

NCT04943575 is a clinical study titled "Study to Evaluate the Efficacy of EZC Pak in Adults With Upper Respiratory Infection (URI)". A randomized-controlled interventional clinical trial to evaluate the effectiveness of EZC Pak \& EZC Pak+D for the treatment of the common cold and/or a URI.

What is the current status of trial NCT04943575?

This trial is currently completed. It is a NA study. The enrollment target is 360 participants. The study started on 2021-06-01. Estimated completion is 2022-01-30.

What conditions does trial NCT04943575 study?

This clinical trial studies the following conditions: Common Cold.

What interventions are being tested in trial NCT04943575?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), EZC Pak (DIETARY_SUPPLEMENT), EZC Pak +D (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT04943575?

This trial is sponsored by PPC Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04943575 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Common Cold

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.